Objective To explore the correlation between serum asprosin levels and bone mineral density (BMD), balance ability and fracture incidence in postmenopausal women. Methods The clinical data of 164 postmenopausal women with osteoporosis (OP) admitted to our hospital were retrospectively analyzed. The patients general clinical data as well as fracture incidence, hip bone density, balance index score (BIS), front-to-front ratio (FBR), and left-right ratio (RLR) were recorded. The correlation between asprosin and BMD, BIS, FBR, RLR and fracture incidence were analyzed. Results The serum asprosin level in the non- fracture group was (3.56±0.54) pg/mL, and the serum asprosin level in the fracture group was (6.56±1.01) pg/mL. There was a statistically significant difference in serum asprosin levels between the two groups (P<0.05); Spearman test results showed that asprosin was negatively correlated with BIS, FBR, RLR and BMD (P<0.05); asprosin and age (r=0.384), height (r=0.343), BMI (r=0.181) was significantly associated with hip BMD (r=0.387), but it had no significant association with body weight (r=0.022, P>0.05). Logistic regression analysis linear regression analysis showed that hip BMD, height, age and BMI were the independent factors affecting asprosin. Conclusions Asprosin may be a risk factor for postmenopausal women with reduced bone density, decreased balance, and fractures. It is closely related to hip BMD, height, age and BMI.

Asprosin; bone mineral density; osteoporosis; balance ability; fracture incidence